Policy and Reimbursement Strategies to Improve Patient Access to Prescription Digital Therapeutics

The U.S. is falling behind in making FDA-cleared prescription digital therapeutics (PDTs) accessible to patients. In their new article in npj Digital Medicine, they highlight how outdated reimbursement policies are creating barriers — and why timely policy action, including a dedicated Medicare benefit, is critical to expanding access, reducing costs, and driving equitable, patient-centered digital care.

Digital therapeutics are transforming treatment for mental health, chronic disease, and more — but only if patients can actually reach them. ATA’s leaders lay out a roadmap to make that future a reality.

Authors:

Andy Molnar
Senior Vice President, Industry Affairs, ATA

Lani Reilly
Vice President, Industry Affairs, ATA

  Read More










Related Resources